Assessing the Prevalence of Metabolic Syndrome in Renal Transplantation
Chronic Renal Failure (CRF)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Assessing the Prevalence of Metabolic Syndrome in Renal Transplantation|
- To evaluate the prevalence of metabolic syndrome in renal transplant patients. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||December 2015|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Metabolic syndrome ( MS) is characterized by the presence of a number of metabolic and hemodynamic disorders such as hypertension (HBP ) , abdominal obesity , dyslipidemia, abnormal glucose metabolism and insulin resistance , resulting in increased cardiovascular morbidity and mortality and the risk for developing type 2 diabetes mellitus.
The concept of metabolic syndrome (MS ) was first described by Reaven in 1988 as a combination of obesity , dyslipidemia , hypertension and fasting hyperglycemia , insulin resistance and inflammation as common pathophysiological disorders in cardiovascular disease (CVD). But the first comprehensive definition of MS was established only in 1998 , the World Health Organization ( WHO ) , in order to facilitate research in this area and points as a key indicator of SM the presence of hyperglycemia and / or resistance to insulin associated with days or more metabolic abnormalities (hypertension, dyslipidemia , obesity, and microalbuminuria).
In the general population , the presence of MS is associated with increased risk of developing diabetes mellitus ( DM ) and cardiovascular disease . Some studies have associated the SM to the appearance of proteinuria and reduction in the value of the glomerular filtration rate ( GFR ), suggesting an association SM with chronic kidney disease ( CKD ) .
Metabolic syndrome (MS) consists of complex disorder that involves assembly cardiovascular risk factors related to abdominal fat deposition and insulin resistance . MS is associated with cardiovascular disease , increasing overall mortality by about 1.5 times and cardiovascular mortality by about 2.5 times.
In 2001 , the National Cholesterol Education Program - Panel of the National Cholesterol Education Program ( NCEP - ATP III ), prepared another proposal. According to the NCEP ATP III, SM represents the combination of at least three components.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01753973
|Contact: Elias David-Neto, MDemail@example.com|
|Contact: Fabiana Agena, MSfirstname.lastname@example.org|
|Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo||Recruiting|
|Sao Paulo, Brazil, 05403-900|
|Contact: Elias David-Neto, MD 55-11-2661-8089 email@example.com|
|Contact: Fabiana Agena, MS 55-11-2661-8089 firstname.lastname@example.org|
|Principal Investigator:||Elias David-Neto, MD||University of Sao Paulo|
|Principal Investigator:||Fabiana Agena, MS||University of Sao Paulo|